NCI_H508_Pooled_Cetux___Trametinib-sc-3582
NCI_H508_Pooled_Cetux___Trametinib
Cetuximab is a targeted monoclonal antibody against the epidermal growth factor receptor (EGFR) which is used therapeutically for the treatment of KRAS wild-type colorectal cancer (CRC) and is currently under trial in combination with the MEK inhibitor Trametinib. The Cetuximab sensitive KRAS wild-type CRC cell line NCI-H508 has been treated with a fixed concentration of ENU for 24 hours and then selected with Cetuximab and Trametinib until drug resistant clones were ready to be picked and grown up as sub-clones of the parental cell line. These will have genes causally implicated in cancer sequenced to identify common point mutations in multiple independently derived drug resistant clones as a forward genetic screen for mechanisms of resistance to Cetuximab and Trametinib combination therapy in CRC
Experiment to identify mechanisms of resistance to Cetuximab and Trametinib combination therapy in colorectal cancer.